Is this your company? Get featured or correct your listing →
Investors
Latest Pulse
- Sep 22, 2026This Fall's Biotech IPOs Are Splitting Into Pops And DropsRecent biotech IPO debuts have split sharply: Parabilis Medicines popped 66.75% and BillionToOne jumped 66.67% on debut, while Electra Therapeutics closed down nearly 12% this week -- a mixed signal inside one reopened window.→
- Sep 14, 2026Three IPOs Set Terms In A $2.1B WeekHoltec Nuclear, Bamboo Insurance and Electra Therapeutics set IPO terms within a day of each other, lining up roughly $1.8 billion of supply; with Orion180's $320 million deal, the week's calendar totals about $2.1 billion.→
- Aug 31, 2026Biotech Funding Held Its Ground While AI Took the OxygenGlobal biotech startup investment is tracking to its usual $36 billion to $40 billion range in 2026 despite the AI capital surge, with more than $6 billion of that going to AI-native drug discovery companies.→
- Jul 7, 2026Biotech's IPO Window Reopens With Record DebutsA run of 2026 biotech IPOs, led by Parabilis Medicines and Kailera Therapeutics, has broken records once held by Moderna, signaling the biotech public-market window has genuinely reopened after years of caution.→
Coverage Timeline
newest firstAll Coverage
Value Add Research
Related Companies
Kailera Therapeutics FAQ
Who are Kailera Therapeutics's investors?
Kailera Therapeutics's investors include Atlas Venture.